Erosion risks

• Generic substitution
• Government price controls and tendering
• Local competition and parallel imports

Leading indicators

• Key Emerging Markets sales growth
• Price/mix vs volume decomposition in segment
• Gross margin trend in segment

Counterarguments

• Many products face low differentiation and price-led competition
• Government tenders can rapidly shift volume to the lowest bidder

Erosion risks

• Therapeutic class commoditization
• Aggressive generic entrants
• Regulatory changes impacting promotions

Leading indicators

• Share trends in key molecules/categories
• Tender win rates where applicable

Counterarguments

• Pharmacies and payers can substitute to cheaper alternatives with minimal friction

Erosion risks

• Platform displacement by competitors
• Hospital and lab consolidation increasing buyer power
• Regulatory changes (e.g., EU IVDR) raising compliance costs

Leading indicators

• Installed base growth of Alinity and other platforms
• Reagent and test volume per installed instrument
• Contract win and renewal rates

Counterarguments

• Large labs can re-bid platforms and switch with enough incentive
• Commoditized assays can face price compression

Erosion risks

• Hospitals standardizing on vendor-neutral middleware and LIS
• Open interfaces reducing lock-in

Leading indicators

• Attach rate of informatics and automation offerings
• Software and services revenue trajectory (if disclosed)

Counterarguments

• Labs can use third-party middleware; software may be less defensible than the instrument and assay ecosystem

Erosion risks

• Loss of WIC contracts at re-bid
• Policy changes to WIC procurement rules
• Reputational damage from quality issues and recalls

Leading indicators

• WIC contract awards and renewals
• Infant formula availability and out-of-stock rates
• Recall and inspection outcomes at pediatric nutrition facilities

Counterarguments

• WIC contracts are periodically re-bid and can shift quickly
• Dependence on government programs can increase volatility

Erosion risks

• Regulatory tightening increasing compliance costs
• Plant disruptions causing supply constraints

Leading indicators

• FDA inspection outcomes and remediation timelines
• Time-to-market for new formulations and pack changes

Counterarguments

• Regulation applies to incumbents too; compliance failures can negate any advantage

Erosion risks

• Brand damage from recalls or social media incidents
• Private label and local manufacturers gaining share

Leading indicators

• Brand sentiment and NPS in key markets
• Market share in infant formula and toddler nutrition

Counterarguments

• Trust can be fragile; a single quality event can cause rapid share loss

Erosion risks

• Consumer trade-down and private label
• Scrutiny of product claims
• Retail shelf-space pressure

Leading indicators

• Organic sales growth in adult nutrition
• Promotional intensity and pricing/mix
• Market share in ONS and disease-specific subcategories

Counterarguments

• Consumers can switch brands quickly based on price and promotions
• Claims-based differentiation can be competed away

Erosion risks

• Channel consolidation increasing buyer power
• E-commerce disintermediation

Leading indicators

• Retail distribution points and shelf share
• Institutional contract wins

Counterarguments

• Large retailers can shift shelf space to private label; distribution advantage can be rented with spend

Erosion risks

• Coverage/reimbursement changes
• Sensor commoditization and price compression
• Rapid innovation cycles reducing differentiation

Leading indicators

• Active users and sensor attachment rate
• Reimbursement expansions or restrictions
• Gross margin trend in Diabetes Care

Counterarguments

• Dexcom and others can win share with superior accuracy/features
• Switching can occur when payers change formularies or new products launch

Erosion risks

• Manufacturing yield issues
• Aggressive pricing by competitors
• Local low-cost entrants in certain geographies

Leading indicators

• COGS per sensor / gross margin (if disclosed)
• Capacity expansions and yield improvements
• Competitive ASP trends

Counterarguments

• Scale can be matched by the other leader; cost advantage may not translate to pricing power

Erosion risks

• Regulatory changes increasing post-market requirements
• Adverse events leading to warnings and recalls

Leading indicators

• FDA/EMA approvals for next-gen sensors and indications
• Post-market safety signals and recall rates

Counterarguments

• Regulation raises costs for everyone and can slow innovation; incumbents are not immune to compliance failures

Erosion risks

• Adverse trial outcomes or safety signals
• Regulatory tightening raising costs
• Reimbursement cuts reducing ROI for hospitals

Leading indicators

• Major product approvals and label expansions
• Safety communications and recalls
• Reimbursement and procedure volume trends

Counterarguments

• Large peers also navigate regulatory pathways; approval alone does not guarantee share

Erosion risks

• New best-in-class technologies
• Hospital value-analysis committees prioritizing price
• Standardization across hospital systems

Leading indicators

• Procedure volume growth by therapy
• Competitive displacement events in key accounts
• Clinical guideline updates

Counterarguments

• Hospitals can switch vendors via tenders; training is replicable across incumbents

Erosion risks

• Patent expirations
• Design-arounds by competitors
• Litigation outcomes

Leading indicators

• Patent cliff timing for major franchises
• IP litigation outcomes
• Next-gen product launch cadence

Counterarguments

• Innovation and clinical data often matter more than patents in many device categories

Erosion risks

• New stimulation modalities from competitors
• Reimbursement pressure
• Adverse outcomes or device issues

Leading indicators

• Procedure volumes and new implant trends
• Competitive win/loss in key accounts
• Clinical evidence releases

Counterarguments

• Competition is intense and surgeons can standardize on other vendors; training is replicable

Erosion risks

• Regulatory findings or recalls
• Post-market surveillance requirements increasing

Leading indicators

• FDA/EMA approvals for new indications
• Recall rates and adverse event trends

Counterarguments

• Regulatory burden is shared by incumbents; differentiation rests on outcomes and features